DARMSTADT, Germany–(BUSINESS WIRE)–Merck, a leading science and technology company, today announced the results of an exploratory analysis from the Phase III JAVELIN Bladder 100 trial with 19…
Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma
DARMSTADT, Germany–(BUSINESS WIRE)–Merck, a leading science and technology company, today announced the results of an exploratory analysis from the Phase III JAVELIN Bladder 100 trial with 19…